- Home
- ALGS vs PSTV Comparison
ALGS vs PSTV Comparison
Compare ALGS & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALGS | PSTV |
|---|---|---|
| Founded | 2018 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.7M | 46.4M |
| IPO Year | 2020 | 2016 |
Fundamental Metrics
Financial Performance| Metric | ALGS | PSTV |
|---|---|---|
| Price | $7.01 | $0.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $46.67 | $6.75 |
| AVG Volume (30 Days) | 57.6K | ★ 10.9M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.81 |
| EPS | N/A | ★ N/A |
| Revenue | $3,611,000.00 | ★ $5,824,000.00 |
| Revenue This Year | N/A | $1.73 |
| Revenue Next Year | N/A | $12.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 18.54 |
| 52 Week Low | $3.76 | $0.16 |
| 52 Week High | $18.99 | $2.31 |
Technical Indicators
Market Signals| Indicator | ALGS | PSTV |
|---|---|---|
| Relative Strength Index (RSI) | 43.11 | 43.76 |
| Support Level | $6.23 | $0.27 |
| Resistance Level | $7.71 | $0.30 |
| Average True Range (ATR) | 0.69 | 0.02 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 41.20 | 91.20 |
Price Performance
Historical ComparisonAbout ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).